MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.

Oncotarget · 2016 · PMC4951307 · PMID 26921265

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a borderline significant trendno p-value reported

As continuous variables, bMMP2 ( p =0.021), but not bMMP9 ( p =0.250) levels were correlated to DFS, whereas bMMP2 ( p =0.098) and bMMP9 ( p =0.068) levels presented a borderline significant trend for correlation to OS.

also in 231 other papers

borderline significanceno p-value reported

This limited number of patients and events could explain the borderline significance of our continuous analysis results.

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.